バイスペシフィック抗体技術を用いた次世代抗体医薬

DOI Web Site Web Site PubMed 被引用文献1件 参考文献3件
  • 井川 智之
    中外製薬株式会社研究本部バイオ医薬研究部

書誌事項

タイトル別名
  • Next Generation Antibody Therapeutics Using Bispecific Antibody Technology
  • Symposium Review バイスペシフィック抗体技術を用いた次世代抗体医薬
  • Symposium Review バイスペシフィック コウタイ ギジュツ オ モチイタ ジセダイ コウタイ イヤク

この論文をさがす

説明

Nearly fifty monoclonal antibodies have been approved to date, and the market for monoclonal antibodies is expected to continue to grow. Since global competition in the field of antibody therapeutics is intense, we need to establish novel antibody engineering technologies to provide true benefit for patients, with differentiated product values. Bispecific antibodies are among the next generation of antibody therapeutics that can bind to two different target antigens by the two arms of immunoglobulin G (IgG) molecule, and are thus believed to be applicable to various therapeutic needs. Until recently, large scale manufacturing of human IgG bispecific antibody was impossible. We have established a technology, named asymmetric re-engineering technology (ART)-Ig, to enable large scale manufacturing of bispecific antibodies. Three examples of next generation antibody therapeutics using ART-Ig technology are described. Recent updates on bispecific antibodies against factor IXa and factor X for the treatment of hemophilia A, bispecific antibodies against a tumor specific antigen and T cell surface marker CD3 for cancer immunotherapy, and bispecific antibodies against two different epitopes of soluble antigen with pH-dependent binding property for the elimination of soluble antigen from plasma are also described.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 137 (7), 831-836, 2017-07-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ